ReviewThe international journal of cardiovascular imaging2026
Cardiac magnetic resonance parametric mapping in patients with thalassemia: Clinical insights into native myocardial T1 mapping and its relationship with T2*. A systematic review.
Review in The international journal of cardiovascular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial iron overload represents a major cause of cardiac morbidity in patients with thalassemia. Cardiovascular magnetic resonance (CMR) T2* is the current reference for noninvasive myocardial iron quantification; however, it may be limited in detecting early iron-related myocardial changes. Native T1 mapping emerged as a complementary technique that may overcome some of the T2* limitations. The aim of this review is to analyze the available evidence on the use of native T1 mapping in thalassemia patients and to evaluate its relationship with T2*. Literature search was performed in PubMed, Scopus, Embase, and Cochrane. Studies evaluating myocardial T1 mapping in thalassemia patients were included. Data extraction focused on study characteristics, technical aspects, T1 and T2* values, and associations between the two measures. Sixteen studies were included. Most investigations reported a good relationship between T1 and T2* values. The strength of this association was higher in iron-overloaded cohorts and weaker in patients with normal T2*. Several studies described a subset of patients with reduced T1 despite normal T2*. Considerable heterogeneity was observed across studies in acquisition protocols, region of interest strategies and native T1 reference values. In conclusion, T1 mapping shows a global, though heterogeneous, association with T2* in thalassemia patients and its systematic integration in acquisition protocols represents a valuable complementary tool to T2*. Native T1 mapping may improve detection of early myocardial iron-related changes and support individualized patient management. Prospective longitudinal studies incorporating clinical outcomes are required to define the prognostic value and clinical role of T1 mapping.
Indexed as
Identifiers
42545611What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.